📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer. (2023)

First Author: Wu MY

Attributed to: G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ccell.2023.04.005

PubMed Identifier: 37116490

Publication URI: http://europepmc.org/abstract/MED/37116490

Type: Journal Article/Review

Volume: 41

Parent Publication: Cancer cell

Issue: 5

ISSN: 1535-6108